July-December North American Biologics Manufacturing Capital Projects, an Industrial Info Market Brief
Attachment: biologics
Starting with insulin three decades ago, biologics have become the fastest-growing class of therapeutic compounds. Sales of biologics are expected to exceed $275 billion annually by 2019. About 300 biologics, which are costly to produce, are now available for human use. These compounds are widely accepted as the most effective means of treating certain diseases, including cancer and rheumatoid arthritis. Industrial Info's Pharmaceutical-Biotech Industry Market Platform is tracking 43 North American biologics manufacturing capital projects worth $2.06 billion that are set for kickoff in the last half of 2018.
